[ Ana Sayfa | Editörler | Danışma Kurulu | Dergi Hakkında | İçindekiler | Arşiv | Yayın Arama | Yazarlara Bilgi | E-Posta ] |
Fırat Tıp Dergisi |
2007, Cilt 12, Sayı 2, Sayfa(lar) 097-101 |
[ Turkish ] [ Tam Metin ] [ PDF ] |
Decreased Adiponectin Levels and Effect of Atorvastatin Treatment in Hyperlipidemic Patients |
Yusuf ÖZKAN1, Handan AKBULUT2, Süleyman Serdar KOCA3, Vedat GENÇER3, Emir DÖNDER3 |
1Fırat Üniversitesi Tıp Fakültesi Endokrinoloji ve Metabolizma Hastalıkları Bilim Dalı, ELAZIĞ 2Fırat Üniversitesi Tıp Fakültesi İmmünoloji Anabilim Dalı, ELAZIĞ 3Fırat Üniversitesi Tıp Fakültesi İç Hastalıkları Anabilim Dalı, ELAZIĞ |
Objectives: Atherosclerotic diseases such as coronary heart disease, myocardial infarction and stroke are leading causes of morbidity and mortality.
Hyperlipidemia is among the major risk factors for atherosclerotic diseases. Atorvastatin, a member of statins wich is a potent lipid lowering drugs is
used widely in hyperlipidemia. Serum levels of adiponectin that is produced in adipose tissue and that regressed atherosclerosis were shown to fall
down in the presence of such atherosclerosis risk factors as hypertension, diabetes and hyperlipidemia. In the present study we aimed to examine
serum adiponectin levels in hyperlipidemia and at the end of atorvastatin treatment.
Material and Methods: The study enrolled 26 non-diabetic hyperlipidemic patients and 10 healthy individuals matching hyperlipidemia group in terms of age, sex, body mass index and blood pressure. The 26 hyperlipidemic patients were treated with 20 mg/day atorvastatin for 8 weeks. Serum lipid and adiponectin levels were examined at the beginning of the treatment and after 8 weeks. Results: Adiponectin levels were found 18.8±6.8 µg/mL in healthy individuals and 3.7±1.3 µg/mL in hyperlipidemic patients, the difference between them being statistically significant (p<0.05). It was established in hyperlipidemia cases that adiponectin level in women was statistically significantly higher than that in men (p<0.05). It was seen that serum adiponectin level increased from 3.7±1.3 µg/mL to 4.7±1.9 µg/mL at the end of the 8-week atorvastatin treatment. Conclusion: Adiponectin level significantly decreases in the presence of hyperlipidemia. Atorvastatin treatment leads to favorable changes in lipid profile and an increase in levels of adiponectin. ©2007, Firat University, Medical Faculty |
[ Turkish ] [ Tam Metin ] [ PDF ] |
[ Ana Sayfa | Editörler | Danışma Kurulu | Dergi Hakkında | İçindekiler | Arşiv | Yayın Arama | Yazarlara Bilgi | E-Posta ] |